Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
With this, for all our USFDA facilities, EIRs are in place
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Both organisations enter into a long- term collaboration to expand patient access in India
The company will provide comprehensive response to USFDA for the observations
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
Subscribe To Our Newsletter & Stay Updated